Use access key #2 to skip to page content.
$19.15 -0.33 (-1.69%)
12/1/2008 4:07 PM

Valeant Pharmaceuticals International (VRX)

CAPS Rating:
***

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating VRX

Add Stock to Watchlist

What the Community Thinks

Total Members

50 Outperforms
15 Underperforms
 

All-Stars

8 Outperforms
6 Underperforms
 

Wall Street

2 Outperforms
1 Underperforms
 

Members bullish on VRX are also bullish on:

Members bearish on VRX are also bearish on:

Ticker Tags

Pharmaceuticals (148), Small Cap (1449), Dermatology (5), Options Backdating (?) (99)
Suggest a tag

Valeant Pharmaceuticals International At A Glance

Current Price: $19.15
Last Trade Time: 12/1/2008 4:07 PM
Open: $0.00
Previous Close: $19.48
Daily Range: $19.00 - $19.50
52-Week Range: $11.00 - $21.00
Volume: 1,070,481
Market Cap: $1.59B
P/E Ratio: 446.75
Compare Our Special Broker Offers!

Stock Trends

VRX VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for VRX

More Headlines...

Top Bull Pitch

Recs

1

Valeant Pharmaceuticals International (VRX)

Avatar crimfunk (< 20) Submitted: 2/02/08 1:21 AM

undervalued, EPS 5 Year Growth (%) 199.82

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Valeant Pharmaceuticals International (VRX)

Avatar tenmiles (99.99) Submitted: 8/22/08 10:03 AM

Technically ripe for 10-15% retracement from current $20.32 level; fundies aren't so hot either - seller here

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 4 of 4  

Recs

0

 (VRX)

Avatar zzlangerhans (99.32) Submitted: 5/14/08 11:39 PM : Underperform Start Price: $15.73 VRX Score: -63.58

Both RESTORE trials showed favorable results, and the stock price has risen correspondingly. However, the eventual revenue prospects for retigabine in the crowded anti-epipleptic market are dubious. The company is downplaying taribavirin and appears to be trying to dish it off to some sucker, I mean partner. As far as revenues from marketed products, I can't improve on the CEO's own comments. "The financial results from this quarter continue to highlight the need for decisive change at Valeant," Chief Executive Officer J. Michael Pearson said in a statement. Translation - we suck. The top commerical priority of the company is to improve their marketing in Mexico. Ahem. Hopefully this pick will bring me back to my rightful position as score leader.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (VRX)

Avatar crimfunk (< 20) Submitted: 2/02/08 1:21 AM : Outperform Start Price: $11.00 VRX Score: 115.11

undervalued, EPS 5 Year Growth (%) 199.82

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VRX)

Avatar hennessy7 (< 20) Submitted: 10/10/07 11:27 AM : Outperform Start Price: $15.56 VRX Score: 70.45

I was long on this stock until my stop loss triggered. Looks like it may trend down before coming back up. Not willing to bet my $ but I will put it on CAPS.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VRX)

Avatar henncoop (95.77) Submitted: 5/16/07 1:30 PM : Outperform Start Price: $15.57 VRX Score: 68.55

near 52 week low

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 4 of 4  

Wall Street

Results 1 - 3 of 3  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackBreanMurray 32.19 10/28/08 Underperform NS $16.80+13.99%-6.49%-20.48
TrackEveillard 28.35 09/30/07 Outperform NS $15.48+23.71%-46.19%+69.89 Toggle the visibility of 60-Second Pitch and replies
TrackSoros < 20 09/30/07 Outperform NS $15.48+23.71%-46.19%+69.89 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 3 of 3  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links